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Background: Over the last decade novel monoclonal CFTR-speciﬁc antibodies have been developed. We here present a paired analysis to detect
wild-type and mutant CFTR using Western blot analysis, ﬂow cytometry and confocal microscopy in several cellular expression systems.
Methods: The following CFTR-speciﬁc antibodies were used; 217, 432, 450, 570, 769, 596, 660, L12B4 and 24.1. Mutant CFTR was detected in
HEK293 cells transiently expressing the mutations; G542X, R1162X, F508del, N1303K, G551D, R117H, A455E.
Results: The majority of these antibodies are suitable for most applications tested. Using immunoﬂuorescence, some antibodies can better detect
mutant forms of CFTR (F508del and N1303K by mAbs 596 and 769), or display lower aspeciﬁc detection by Western blot analysis (mAbs 432,
450, 769 and 596) or immunoﬂuorescence (mAbs 432, 450, 570 and 769).
Conclusion: Optimal detection of CFTR by monoclonal antibodies depends on CFTR mutation and the speciﬁc research application.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Mutant CFTR; Monoclonal antibodies; Confocal microscopy; Flow cytometry; Western blot; Paired analysis1. Introduction
1.1. Background
Cystic Fibrosis (CF) is caused by mutations in the gene
encoding for the Cystic Fibrosis transmembrane conductance
regulator (CFTR) protein [1]. CFTR functions as cyclic AMP
(cAMP)-activated chloride channel at the apical membrane of
epithelial cells [2]. The majority of the CFTR protein is located
intracellularly, and contains two membrane-spanning domains
(MSD1 and MSD2), two nucleotide-binding domains (NBD1⁎ Corresponding author at: Department of Pediatric Pulmonology, University
Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands
Tel.: +31 88 755 3201; fax: +31 88 755 4747.
E-mail address: J.Beekman@umcutrecht.nl (J.M. Beekman).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Pub
http://dx.doi.org/10.1016/j.jcf.2012.12.005.lishedand NBD2), and a unique regulatory (R) domain that allows
phosphorylation-dependent gating [3,4].
Over 1800 mutations (www.genetic.sickkids.on.ca/cftr/app)
in CFTR have been associated with FC and these have been
classified into six different groups according to their impact on
CFTR function [5]. Class I mutations such as G542X and
R1162X encode for premature stop codons and affect CFTR
protein translation [6]. The most common mutant CFTR allele
contains a phenylalanine deletion at position 508 (F508del)[7],
and is classically recognized as a class II mutation (like N1303K)
that leads to incorrect folding and retention in the endoplasmic
reticulum (ER) from where it is degraded. This is indicated by
severe reduction or absence of the complex-glycosylated form of
CFTR (C-band) and expression of the core-glycolysated form of
CFTR (B-band)[8,9]. Class III (G551D) and IV (R117H)
mutations affect gating and chloride conductivity, respectively,
but display normal trafficking [6,10,11]. Reduced amount ofby Elsevier B.V. All rights reserved.
488 M.A. van Meegen et al. / Journal of Cystic Fibrosis 12 (2013) 487–496functional CFTR is observed for class V (A455E) and VI
mutations, due to impaired biosynthesis and decreased stability
of the CFTR protein, respectively [5,12]. However, many CFTR
mutations cannot be strictly classified into single classes as was
shown for A455E and F508del [12–14]. The impact of many
other CFTR mutations on CFTR biology still requires further
attention.
The Cystic Fibrosis Foundation provides the CF research
community with multiple monoclonal (mAbs) Abs for research
applications. A paired analysis for these antibodies is currently
missing in literature. We compared these antibodies with some
commercial antibodies that have previously been used to compare
our study results with previous studies [15–18]. In addition to
pre-existing literature on these commercial antibodies, we
assessed their capacity to specifically detect CFTR by flow
cytometry. Furthermore, we assessed their capacity to detect
various CFTR mutants, belonging to the different mutational
classes. We show that most mAbs are capable of detecting
(mutant) CFTR by Western blot analysis. However, using
immunofluorescence approaches we observed specific recogni-
tion for CFTR mutants by some mAbs, which could have
implications for CFTR detection in primary tissue derived from
CF patients. The overview presented here can be important for
analysis of (mutant) CFTR expression in specific research
applications using cell lines or primary tissue derived from
patients.2. Material and methods
2.1. Primary antibodies
The following CFTR-specific antibodies were used: mono-
clonal antibody (mAb) 24.1 (mouse IgG2a, R&D systems,
Minneapolis, MN) and mAb L12B4 (mIgG2a, Chemicon
international; Temecula, CA). The following antibodies were
obtained via the Cystic Fibrosis Foundation Therapeutics
(www.cftrfolding.org/CFFTReagents.htm) mAbs 217, 432,
450, 570 and 769 (mIgG1), 660 and 596 (mIgG2b) [19–22].
We compared 2 μl of CFF antibodies with 2 μg of mAb L12B4
upon SDS-PAGE and coomassie and found concentrations of
approximately 1 μg/μl for mAbs 432, 450 and 596, and of
2.5 μg/μl for mAbs 217, 570, 769 and 660 (Supplementary Fig.
1). Polyclonal HSP90 was purchased from Dr. Ineke Braakman
(University of Utrecht, Utrecht, The Netherlands).2.2. Cell culture
Baby hamster kidney cells (kindly provided by Dr. G.L.
Lukacs, McGill University, Montreal, Canada) and human
embryonic kidney cells (HEK293, ATCC, Manasses, VA) were
grown as described [23,24]. Calu-3 cells (ATCC) were cultured
in minimal essential medium according to the manufacturer's
protocol (ATCC) containing 10% fetal calf serum. Human
bronchial epithelial cells CFBE41o− cells (CFBE) [25] were
grown as described previously [26].2.3. CFTR knockdown
Four pre-designed siRNAs for CFTR were purchased
(#1 GAACACAUACCUUCGAUAU; #2 GUACAAACAUG
GUAUGACU; #3 GUGAAAGACUUGUGAUUAC; #4 GC
AGGUGGGAUUCUUAAUA) (Thermo Fisher scientific,
Lafayette, CO). Transfection with a non-targeting pool of
siRNA was used as control. CFBE cells stably transduced with
either wild-type CFTR or F508del-CFTR were seeded in 70 cm2
dishes and transfected at 60% confluence with 20 nM siRNA
using Lipofectamine RNAiMAX (Invitrogen, Bleiswijk, The
Netherlands) according to the manufacturer's instructions. CFTR
analysis was performed 48 h post-transfection.
2.4. DNA constructs and transfection
CFTR mutants were prepared by QuickChange® (Stratagene,
La Jolla, CA) site-directed mutagenesis on pcDNA3-CFTRwt
[27] using Phusion polymerase (New England Biolabs, Ipswich,
UK) and were sequence verified. pcDNA-F508del was previ-
ously described [27]. Primers were designed to extend approx-
imately 15 bp up and downstream of the site of mutagenesis. The
PCR program used was: 98 °C for 1 min, followed by 25 cycles
98 °C for 25 s, 55 °C for 25 s and 72 °C for 10 min, and final
elongation at 72 °C for 10 min. HEK293 cells were transfected
with plasmid using polyethylenimine (Polysciences, Eppelheim,
Germany)-DNA complexes as described [28]. CFTR analysis
was performed 48 h post-transfection.
2.5. Western blot analysis
Cells were lysed in Laemmli buffer [24] in the presence of a
protease inhibitor cocktail (HALT, Thermo scientific, Rockford,
IL), incubated for 30 min at 37 °C, and passed through a 21G and
a 25G needle to reduce viscosity. Protein samples were quantified
as described [29] and 10–35 μg of total protein was separated on
a 6–8% SDS-polyacrylamide gel, and prepared for Western Blot
as described [24]. Dilutions of CFTR mAbs are indicated in
Tables 1A, 1B.
2.6. CFTR detection by immunofluorescence
Cells were plated in wells containing microscope glasses
allowing the plastic adhered cells to be analyzed by flow cytometry
and glass-adhered cells by confocal microscopy. In addition, 10%
of EGFP plasmid DNA was included. Cells were detached using
5 mM EDTA in PBS and intracellular staining for CFTR by flow
cytometry was performed as described before [24]. Subclass
specific goat anti-mouse Dylight 649-conjugated (1 μg/ml)
secondary antibody (Jackson Immuno Research, West Grove,
PA) was used to detect CFTR-mAbs. Cells were resuspended
in PBS containing 2% FCS and 2 mM EDTA and analyzed by
flow cytometry using a FACS Canto (BD, San Jose, CA) or
prepared for confocal microscopy using a Zeiss LSM710 and
63× objectives (Zeiss, Heidelberg, Germany) as described
[24].
Table 1A
Overview of the anti-CFTR antibodies to detect (mutant) CFTR by Western blot, flow cytometry and confocal microscopy.
CFTR mAb Western blot Flow cytometry Confocal microscopy
Dilution BHK CFBE Calu-3 HEK 293 Used dilution or
concentration
BHK CFBE HEK 293 Used dilution or
concentration
BHK Calu-3 CFBE HEK 293
217 1:1000 + + ++ + 1:333 + +/− − 1:333 − +/− − −
432 1:1000 ++ ++ + ++ 1:250 ++ ++ ++ 1:250 + − − ND
450 1:1000 ++ ++ ++ ++ 1:250 ++ ++ ++ 1:250 + ++ + +
570 1:1000 + ++ + + 1:250 ++ ++ + 1:250 ++ ++ + ND
769 1:1000 ++ ++ ++ ++ 1:250 ++ ++ ++ 1:250 + ++ − ND
596 1:1000 ++ + ++ ++ 1:500 − + + 1:500 + + − +
660 1:1000 ++ −1 +/− +/−1 1:1000 − +/− − 1:1000 +/− +/− − −
24.1 1:1000 + +/− + + 3 μg/ml + + ++ 3 μg/ml + +/− − ND
L12B4 1:1000 ++ +/− ++ +/− 14 μg/ml +/− +/− +/− l4 μg/ml − + − ND
Abbreviations: BHK; baby hamster kidney, CFBE; Cystic Fibrosis Bronchial Epithelial cells, HEK; human embryonic kidney, ND; not determined.
++: good detection, + reasonable detection, +/− detection above background, −: no specific detection.
1. specific CFTR detection, however, aspecific band around 150 kD observed.
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3.1. Detection of (mutant) CFTR by Western blot analysis
We aimed to determine which of the CFTR-specific antibodies
is most suitable for CFTR detection by Western blot analysis, and
immunofluorescence using flow cytometry or confocal microsco-
py. An overview of the different antibodies and the immunizing
epitopes are schematically represented in Fig. 1. First, Western
blot analysis was performed for CFBE cells transduced with
wild-type (wt) or F508del-CFTR, and Calu-3 cells that endoge-
nously express CFTR (Fig. 2). CFTR was detected by all
antibodies as indicated by immunoreactivity of complex-
glycosylated CFTR around 170 kDa (C-band) in wt-CFTR-
expressing CFBE cells that was reduced upon targeting by
inhibitory RNA. F508del was detected around 150 kDa in CFBE
cells corresponding with the core-glycosylated protein present in
the ER (B-band). CFTR in Calu-3 cells consistently migrated
around 160 kDa. Limited non-CFTR-specific signal was ob-
served for mAbs 432, 450, 769, and 596. Monoclonal antibodies
217 and 660 displayed strong immunodetection of proteins
around 70 and 150 kDa, respectively, which was unaffected by
CFTR inhibitory RNA indicating aspecific reactivity. SomeTable 1B
Overview of the CFTR-directed antibodies to detect mutant-CFTR relative to









596, 769, 24.1 , 570, 432,450
570, 432, 450
570, 432, 450, 24.1, 769, 596
570,
570,
596, 769, 24.1, 432, 450
596, 769, 24.1, 432, 450
769, 596, 570, 24.1, 432, 450aspecific immunoreactivity around 70 kDa was also observed for
mAb 570. For the commercial mAbs L12B4 and 24.1,
CFTR-specific signal was detected but limited compared to the
CFF mAbs, however these results varied between batches,
especially for L12B4. Analysis of HSP90 levels indicated equal
loading (Fig. 2B).
We next assessed detection of CFTR mutants by Western
blot analysis (Fig. 2C). We selected wt-CFTR, F508del (class
II), G542X (I), R1162X (I), G551D (III), R117H (IV), A455E
(V), and N1303K (II) that were ectopically expressed in
HEK293 cells. Overall, non-CFTR-specific signal (empty
vector transfected) for these mAbs in HEK293 cells were
comparable to CFBE cells. Again, mAb 660 also recognized a
non-CFTR product around 150 kDa, which complicated
recognition of CFTR B-band. G542X could only be detected
by L12B4 (50 kDa) and R1162X was detected around 110 kDa
but not using NBD2 and C-terminal-specific mAbs. Class II
mutations are considered to be severe mutations and can be
recognized by high B–C band ratio. We observed for F508del
lower expression levels of B and C-band compared to N1303K.
Expression of G551D (class III) and R117H (class IV) was
comparable to wt-CFTR. For class V mutant A455E, the
majority of the protein was core-glycolysated band B and only
limited complex-glycosylated CFTR (C-band) was observed.
We observed no preferential recognition of the mAbs for the
CFTR mutants by Western blot analysis. Loading of the
Western blots was similar between lanes as shown by HSP90
detection (Fig. 2D) and coomassie staining (Supplementary
Fig. 2). Transfection efficiency was found comparable as
indicated by detection of neomycin phophotransferase II that
was expressed from the CFTR-expressing plasmid (Fig. 2E).
To conclude, all antibodies detected CFTR on Western blot,
however, low aspecific detection indicated that mAbs 432, 450,
769, and 596 were most optimal for detection of mutant CFTR
alleles that are associated with reduced expression.
3.2. Detection of (mutant) CFTR by flow cytometry
We next compared the CFTR-specific mAbs in immunofluo-
rescence. In contrast toWestern blot analysis, CFTR conformation
Fig. 1. Schematic representation of CFTR and immunizing epitopes of the mAbs used in this study.
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affect the binding to specific mAbs. We assessed whether these
mAbs could specifically detect CFTR by flow cytometry by
performing siRNA-mediated knockdown of CFTR in CFBE cells,
and splitting cells from a single transfection to analyze binding of
CFTR-specific mAbs. In Fig. 3A, data for each antibody is
depicted using optimal mAbs concentrations (Table 1A). CFTR
was specifically detected using mAbs 432, 450, 570, 769, 596 and
24.1 in CFBE cells. Highest CFTR specificity was identified for
mAbs 450, 432, 570 and 769 with ratios (signal intensity of
control knockdown/CFTR knockdown) above 4. CFTR mAbs
24.1 and 596 displayed intermediate specificity (ratios between 2
and 4). Specificity was lowest (b2) for mAbs L12B4, 217 and 660
indicating high aspecific background staining. Interestingly,
F508del-CFTR was detected at 79, 71 and 66 percent of
wt-CFTR levels for mAbs 596, 432 and 769, respectively,
indicating high binding of these mAbs to F508del-CFTR in CFBE
cells. Intermediate F508del-CFTR recognition was observed for
mAbs 24.1, 570 and 450 at 44, 21 and 10 percent of wt-CFTR.
The data indicated that most mAbs can recognize wt-CFTR by
using flow cytometry, although specificity is lowest for mAbs
660, 217 and L12B4. Relative to wt-CFTR mAbs 596, 432 and
769 detected highest levels of F508del-CFTR.
We next analyzed CFTR expression levels of other CFTR
mutants relative to wt-CFTR in HEK293 cells (Fig. 3B). First,
we analyzed serial dilutions of the CFF mAbs in HEK293 cells
expressing wt-CFTR or control transfected to determine
optimal antibody concentration in these cells to detect CFTR
(Supplementary Fig. 3A and B). In the experiments, the relative
levels of wt-CFTR compared to the transfected mutants were
identical as HEK293 cells were transfected with the various
constructs and incubated with the various antibodies at the
same time. Again, we observed preferential binding of mAbs to
specific CFTR mutants by determining the relative expression
of mutant CFTR with respect to wt-CFTR for each antibody
(Table 1B; data for each CFTR mutation is displayed in
Supplementary Fig. 3C). Upon ectopic expression in HEK293
cells mAbs 432, 450 and to a somewhat lesser extent 570 (all
R-domain) displayed similar recognition of the CFTR mutants.
G551D was expressed at levels comparable to wt-CFTR,
expression of R117H, N1303K, A455E and R1162X was
intermediate, and low levels were observed for F508del and
G542X. Expression of R117H and N1303K by mAb 570 washigher compared to the other R-domain mAbs. The NBD2
selective mAbs 769 and 596 indicated higher expression
of F508del and N1303K and lower expression of G551D
compared to the R-domain antibodies. As expected, expres-
sion levels for R1162X were similar to empty vector, however,
some expression was consistently observed for G542X,
possibly due to production of an alternative transcript from
this cDNA construct downstream of position 542. High
background levels as indicated by staining of control transfected
cells prevented specific detection of CFTR for mAbs 217, 660
and L12B4. Transfection efficiency was similar for all
constructs as indicated by identical co-transfection with EGFP
(Fig. 3C).
In conclusion, mAbs 432, 450, 570, 769 and 24.1 can be
used to study CFTR expression by flow cytometry. Some
mAbs preferentially recognized CFTR mutants as indicated by
strong recognition of F508del and N1303K by mAbs 596 and
769, and high recognition of G551D by R-domain selective
mAbs.
3.3. CFTR detection by confocal microscopy
Last, CFTR-specific antibodies were compared by confocal
microscopy. Staining was compared in wt, F508del and
non-transfected BHK cells (Fig. 4A; flow cytometric analysis
of these cells for most antibodies are described previously [24]).
In these cells, wt-CFTR was detected at the plasma membrane
as well as throughout the cytoplasm, and was easily detected
using mAbs 432, 450, 570, 596, 769 and 24.1. Interestingly,
mAbs 450, 769 and 596 also significantly detected expression
of F508del, whereas for others mAbs intensities between wt-
and F508del-CFTR were more comparable with Western blot
analysis (data not shown). MAbs 217 and 660 also detected
CFTR (wt and F508del) but showed background staining.
Ectopic CFTR was poorly recognized by mAb L12B4 in these
cells. In Calu-3 cells we assessed the CFTR antibody panel for
CFTR recognition by immunocytochemistry by comparison
with subclass specific isotype control antibodies (Fig. 4B). Almost
all antibodies showed clear increased fluorescent intensity, though
this was limited for mAb 432. Staining was observed mostly
throughout the cytoplasm with some plasmamembrane staining.
Nuclear staining was clearly observed for monoclonal antibody
217 and to a lesser extent for mAb 596 (upper cells). These results
Fig. 2. CFTR detection by Western blot analysis. Detection of CFTR by Western blot analysis with the following antibodies: 217, 432, 450, 570, 769, 596, 660,
L12B4 and 24.1. C-band indicates the fully-glycosylated form of CFTR around 170 kDa and B-band the ER core-glycosylated form around 150 kDa. A. Membranes
were prepared using 30 μg of protein of CFBE cells expressing wt-CFTR or F508del-CFTR and transfected with non-(lane 1 or 3) or CFTR-targeting siRNA (lane 2
or 4), or endogenously CFTR-expressing Calu-3 cells (lane 5). One representative of three independent experiments is shown. B+D. HSP 90 was visualized as a
loading control. C. Western blots containing 25 μg of total protein of HEK293 cells transiently transfected with pcDNA3 containing; CFTR-wt, F508del, G542X,
R1162X, G551D, R117H, A455E, N1303K or empty vector. E. Neomycin phosphotransferase II was used as a transfection control.
491M.A. van Meegen et al. / Journal of Cystic Fibrosis 12 (2013) 487–496are in concordance with our observations in human nasal epithelial
cells [24]. For the CFBE cells, CFTR was most specifically
detected with mAbs 450 and 570 (Fig. 4C), which we alsoobserved with flow cytometry using these cells. All other mAbs
showed no clear differences in fluorescent intensity between wt-
and F508del-CFTR CFBE cells (data not shown).
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cells by confocal microscopy, we selected three CFTR antibodies
based on CFTR-(mutation) specific recognition by flow cytom-
etry (Fig. 3). We compared the phosphorylation-sensitive mAb
450 which displayed high wt-CFTR specificity, mAb 596 that
preferentially recognized F508del and N1303K, and mAb 660
that displayed poor CFTR-specific detection in HEK293 cells.
We observed no obvious differences in immunolocalization,
althoughwe found differences in staining intensities.Monoclonal
antibody 450 detected wt-CFTR, G551D, R117H and N1303K
(Fig. 4C). Limited detection was observed for R1162X and
A455E.Mutant CFTRG542X and F508del could not be detected
by mAb 450. The NBD2-selective mAb 596 could recognize
wt-CFTR, G551D, R117H and N1303K equally (Fig. 4C).
Detection of CFTR was limited for F508del and A455E and
CFTR mutants G542X and R1162X were not detectable. No
differences in staining pattern for the various mutants were
observed by mAb 660, suggesting binding to a non-CFTR
product as already indicated byWestern blot and flow cytometry.
In conclusion, mAbs 450, 570, 769 and 596 are suitable for
CFTR detection by confocal microscopy.Fig. 3. Detection of CFTR by flow cytometry. Cells were prepared 48 h after transfec
the CFF Abs (1:250–1:1000) dilutions were used, for mAb L12B4 14 μg/ml and
(mean±SEM). A. Specificity of the CFTR antibodies in human airway epithelial ce
combination with control or CFTR siRNA-mediated silencing. CFTR specificity was
CFTR knockdown and is indicated within brackets. Highest CFTR specificity was ide
(2.2) and 596 (2.1) displayed intermediate specificity. Specificity was lowest for L1
CFTR-mutant, expression levels were determined in the GFP-positive cells and co
CFTR-mutants to control for transfection efficiency. One representative of three ind4. Discussion
The CFF provides the CF research community with a panel
of monoclonal antibodies to study CFTR. Here, we present a
direct comparison of these antibodies for their use in Western
blot, flow cytometry and confocal microscopy. Our results are
summarized in Tables 1A, 1B, and indicate that the majority of
these antibodies are suitable for most applications tested. Still,
some mAbs are superior to others with respect to recognition of
mutant forms of CFTR, or displayed lower aspecific detection.
Our primary antibodies of choice for Western blot are mAbs
432, 450, 769 and 596. These could both recognize wt and
mutant forms with high specificity. The mAbs 217, 570 and
660 also strongly recognized non-CFTR proteins as indicated
by CFTR RNA interference. MAb 660 recognized a non-CFTR
product that migrated somewhat faster than CFTR B-band, and
is therefore less suited for Western blot analysis. Detection of
CFTR mutants by these mAbs on Western blot did not reveal
preferential recognition.
For detection of CFTR by flow cytometry, we observed
highest CFTR specificity using mAbs 432, 450, 570 and 769.tion, and CFTR expression is indicated by mean fluorescent intensity (MFI). For
24.1 3 μg/ml. One representative of three independent experiments is shown
lls was assessed in wt-CFTR or F508del-CFTR transduced CFBE41o− cells in
expressed as the ratio between signal intensity of control knockdown divided by
ntified for mAbs 450 (7.5), 432 (5.5), 570 (4.8) and 769 (4.3). CFTR mAbs 24.1
2B4 (1.5), 217 (1.3), and mAb 660 (1.3). B. In HEK293 cells transfected with
mpared to wt levels for each experiment. C. EGFP was co-transfected for all
ependent experiments is shown.
Fig. 3 (continued).
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cellular expressions systems, while for mAbs 217, 596, 660 and
L12B4 relative high MFI levels were observed for empty vector
transfected HEK293 cells or CFBE cells treated with CFTR
siRNA. Importantly, we found selectivity of some mAbs for
specific mutant forms of CFTR, as the R-domain-specific
antibodies poorly recognized F508del and N1303K compared
to the NBD2-directed antibodies, but excelled in recognition of
G551D (Table 1B). MAbs 217, 660 and L12B4 were not suitable
for flow cytometry due to low specificity.
For confocal microscopy, the majority of the antibodies are
able to recognize wt-CFTR in BHK and Calu-3 cells stably
expressing CFTR. In addition, some CFTR antibodies could also
recognize F508del-CFTR, which is in concordance with Mall et
al., who also observed F508del-CFTR expression with mAb 596
and 769 [22]. However in CFBE cells only mAb 450 and 570
showed specific CFTR staining. This could probably be
explained by the lower wt-CFTR levels in CFBE cells as
compared to BHK cells and the highly selective recognition ofCFTR by mAbs 450 and 570 as we also observed in flow
cytometry. Although we could verify that specific mAbs show
preference for distinct CFTR mutants by confocal microscopy as
indicated by different staining intensity, these differences were
less clear compared to flow cytometry. Furthermore, we could
not observe clear differences in CFTR localization between
CFTR mutants. This might be related to experimental conditions
resulting from CFTR overexpression, as we previously observed
clear preferential recognition of CFTR at the subapical region for
mAb 450 and 570 in primary nasal epithelium, whereas other
mAbs show apical membrane labeling [24].
Our paired analysis showed similar recognition of mutant
CFTR by all CFTR antibodies by Western blot. In contrast,
preferential recognition of CFTR mutations F508del and N1303K
by NBD2 antibodies 596 and 769 was observed by flow
cytometry. Flow cytometry is ideally suited to quantify
cell-associated fluorescence. Selectivity for mutants could be
explained by differences in interacting proteins between CFTR
mutants, post-translational modifications such as phosphorylation
Fig. 4. Detection of CFTR by confocal microscopy. Cells were incubated with anti-CFTR antibody (see Fig. 3) and thereafter with a subclass-specific secondary antibody conjugated to DyLight 649 (red). Nuclei are
indicated by DAPI (blue). The right panel shows a merge of all staining. A. Comparison of the specificity of nine anti-CFTR antibodies in wt-CFTR, F508del or non-transfected BHK cells (EV). B. Calu-3 cells, which
endogenously express CFTR were incubated with nine CFTR-specific antibodies, and compared with isotype-matched control antibodies. C. CFBE cells transduced with wt-CFTR or F508del-CFTR were incubated
with CFTR antibody 450, 570 or isotype control (IgG1). D. Reactivity of mutant CFTR in HEK293 cells after transient transfection with GFP and mutant CFTR (see Fig. 2). Cells were incubated with CFTR antibody
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sensitive antibodies are used as indicated by Hegedüs et al. [21], or
conformational changes. Interacting proteins may play a role in the
differences in CFTR detection between the various cell lines as we
observed relative higher F508del expression levels for mAb 432 in
CFBE cells (Fig. 3) when compared to HEK293 cells (Fig. 3) and
BHK cells (Fig. 4). Furthermore, fixative, permeabilization and
other experimental procedures may affect CFTR detection.
Our data also provides novel insights into defects of mutant
CFTR. We observed for mutant N1303K considerable C-band
expression (complex-glycosylated CFTR) by Western blot
analysis, and relative high CFTR protein levels by flow
cytometry compared to F508del. This may suggest that the
N1303K mutation also affect gating or conductivity as this
mutant is associated with severe CF (http://cftr2.org). These data
are in accordance with He et al. [30], but conflicts with others that
observed no C-band [31]. Furthermore, we confirmed [31,32]
and expanded data on mutant G551D and R117H by demon-
strating with Western blot and flow cytometry that expression
and trafficking were not affected. Interestingly, for mutant
A455E we demonstrated CFTR protein levels slightly higher
than mutant F508del, with comparable B–C ratio (quantificationnot shown), suggesting that trafficking is impaired as well.
A455E is considered to be a mild mutation as it is associated with
pancreas sufficiency (http://cftr2.org), indicating that the limited
levels of A455E C-band have increased activity as compared to
N1303K and F508del, as previously noted [33], or that some
A455E B-band may have activity at the plasma membrane as has
been described for F508del [34].
This article provides a direct comparison of multiple
CFTR-specific mAbs and provides suggestions for their use in
various applications. Furthermore, we provide more insight on the
impact of CFTR mutations N1303K, A455E, G551D and R117H
on CFTR expression. We demonstrated that most mAbs are
capable of detecting (mutant) CFTR byWestern blot, but that clear
preferences can be observed for CFTR mutants when CFTR is
detected by immunofluorescence. Mutation-specific detection of
mAbs can be an important confounding factor when analyzing
mutant CFTR expression by immunofluorescence in native
tissue and may underlie different conclusions regarding CFTR
expression and localization in native tissue. Our study may further
aid to define protocols that measure F508del-CFTR expression and
localization in personalized medicine approaches for CFTR-
restoring compounds.
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